Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Part of story

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.

Oct 5, 20263 sourcesVaccine development Clinical trials

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Other sources for this story

Reuters

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial | Reuters

BioPharma Dive

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Part of story

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Other sources for this story

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial | Reuters

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Part of story

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Other sources for this story

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial | Reuters

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data